In order to increase the access to treatment and therefore the quality of life of these patients, Farmaceutica REMEDIA S.A. sustains the patients associations to increase the budgetary allocation for this disease, becoming a traditional friend of the Romanian Association of  Hemophilia.

Farmaceutica REMEDIA S.A., in partnership with Baxter, was one of the main sponsors of the Symposium organized by the Romanian Association of  Hemophilia on the occasion of the International Hemophilia Day on April 15, 2011.

The exact number of patients with hemophilia from Romania is not known, du to the lack of a national register. According to the patient associations and authorities, there are approximately between 1000 and 2000 people suffering from this rare disease.

It is known that the treatment of a patient in Romania is about 0.5 units per capita, while the average is about 2.2 units.

For comparison, in Hungary, a country with a socio-economic level similar to Romania, 3% from the National Insurance House budget is allocated to hemophilia.

In other words, treatment is 7.1 units per capita, a figure that places Hungary on the fourth place in Europe.

All these information were presented at the Symposium organized by the Romanian Association of Hemophilia at the International Hemophilia Day.

On this occasion, the organizers announced the establishment of a Twinning Program partnership with a Hungarian Association. This “brotherhood” helps both organizations, one to learn and the other to share their experience, so that the Romanian hemophilia patients could improve their access to the treatment and, consequently, the quality of life.

Together with the representatives of the Romanian and Hungarian patients, the symposium was attended by Prof. Dr. Margit Serban, honorary President of the Romanian Hemophilia Association.

Mrs. Prof. Dr. Margit Serban showed her full support to the patients as a physician and expressed the hope that the Hungarian model will be also implemented by the Romanian Ministry of Health officials.

The Counselor of the Health Minister, Dr. Andrew Kozma, mentioned the intentions of the Ministry to allocate more founds to for patients with hemophilia and to improve their access to treatment through the availability of cheaper but equally effective products.

The ministerial adviser said that efforts are made for the treatment to contain a number of units closer to the European average, but did not mention how long this process will take place.